Home HOME Neoplasma 2022 Neoplasma Vol.69, No.2, p.383–391, 2022

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.2, p.383–391, 2022

Title: The Hu antigen R/interferon-β axis modulates sensitivity of esophageal squamous cancer cells to cisplatin
Author: Ya-Yun Cui, Xiao-Feng Zhu, Shu Zhang

Abstract: The incidence rate of esophageal squamous cell carcinoma (ESCC) has risen significantly in recent years. RNA binding protein (RBP) has been attracting increased attention in the treatment of ESCC. Therefore, the primary aim of this study was to explore the roles of the RBP Hu antigen R (HuR) in ESCC. The mRNA levels were detected via reverse transcription-quantitative PCR, while the expression levels of protein were evaluated using western blotting. Cell proliferation was estimated by cell counting kit-8 assay and colony formation assay. Flow cytometry was applied to measure cell apoptosis. Luciferase assay and RIP assay were applied to verify whether interferon-β (IFN-β) was targeted by HuR. The results unambiguously demonstrated that HuR was upregulated in ESCC. Overexpression of HuR alleviated chemosensitivity to cisplatin in ESCC cells, as evidenced by increased cell proliferation and decreased apoptosis. Moreover, IFN-β was found to be a target of HuR and downregulated in ESCC cells. And overexpression of IFN-β abrogated the effects of HuR on cisplatin-sensitivity of ESCC cells. Taken together, these findings suggested that HuR may alleviate the chemosensitivity of ESCC cells to cisplatin via binding to IFN-β. Therefore, the HuR/IFN-β axis may be a novel biomarker for improving the chemosensitivity of ESCC.


Keywords: Hu antigen R; interferon-beta; cisplatin sensitivity; esophageal squamous cell carcinoma
Published online: 28-Feb-2022
Year: 2022, Volume: 69, Issue: 2 Page From: 383, Page To: 391
doi:10.4149/neo_2022_210910N1299
Price: 18.90 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.